on DBV TECHNOLOGIES (EPA:DBV)
DBV Technologies is participating in a healthcare innovation conference
DBV Technologies announced that its CEO, Daniel Tassé, will participate in a discussion at the 2nd Annual Guggenheim Healthcare Innovation Conference. The event will be held on November 11 in Boston. The discussion will be streamed live on the company's website. A recording will be available for 90 days.
DBV Technologies, listed on Euronext and Nasdaq, develops treatments for food allergies. It uses VIASKIN® technology to retrain the immune system via the EPIT method. This non-invasive approach is currently being tested on young children with peanut allergies.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all DBV TECHNOLOGIES news